This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of teriflunomide
MSMED_TERIFLUNOMIDE
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
395 |
4. Check minimum number of events
Min. number of events
3
|
395 |
5. Include endpointsNone |
395 |
6. Filter based on genotype QC (FinnGen only) |
395 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Use of teriflunomide
based on the number of shared cases.
Similar with more cases:
- MS-disease / Multiple Sclerosis
- Demyelinating diseases of the central nervous system
- L04AA Selective immunosuppressants
- Other degenerative diseases of the nervous system
- ILD medications: immunosuppressive drugs
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 395 | 294 | 101 |
| Unadjusted period prevalence (%) | 0.09 | 0.10 | 0.04 |
| Median age at first event (years) | 44.65 | 45.13 | 43.28 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 349
- Matched controls
- 3488
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
3651.1
323.0
334
20
L04AA31
ATC
teriflunomide; oral
+∞
323.0
349
*
G35
ICD-10 Finland
Multiple sclerosis
+∞
323.0
349
28
109
Kela drug reimbursment
Multiple sclerosis
8598.0
323.0
344
24
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
+∞
323.0
349
19
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
53.2
183.8
228
119
L03AB07
ATC
interferon beta-1a; parenteral
322.9
178.9
168
10
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
165.7
139.8
140
14
L03AX13
ATC
glatiramer acetate; parenteral
175.8
124.9
125
11
H46
ICD-10 Finland
Optic neuritis
98.8
106.5
114
17
N86
ICPC
Multiple sclerosis
166.1
103.8
105
9
TAB00
NOMESCO Finland
Lumbar puncture
28.1
100.3
142
83
L03AB08
ATC
interferon beta-1b; parenteral
177.8
81.0
82
6
L04AX07
ATC
dimethyl fumarate; oral
187.0
73.2
74
5
C10AC01
ATC
colestyramine; oral
36.4
66.8
86
31
N07XX09
ATC
[U] dimethyl fumarate; oral
202.6
65.5
66
*
N04BB01
ATC
amantadine; oral
48.2
65.4
79
21
164
Kela drug reimbursment
Fingolimod
83.3
56.3
62
9
353
Kela drug reimbursment
Cladribine and fingolimod
77.7
47.7
53
8
XA800
NOMESCO Finland
Neuropsychological investigation
18.4
47.4
75
51
G04BD12
ATC
mirabegron; oral
13.0
46.0
85
84
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
9.7
41.3
90
121
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
31.7
40.9
54
20
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
25.9
40.8
57
26
L04AA27
ATC
fingolimod; oral
77.1
36.9
41
6
R20.2
ICD-10 Finland
Paraesthesia of skin
8.4
36.6
87
133
XKD00
NOMESCO Finland
Uroflowmetry
9.5
34.5
75
98
XKD06
NOMESCO Finland
Physiologic investigation of micturition
24.5
33.2
47
22
M03BX01
ATC
baclofen; systemic
23.3
31.4
45
22
2AB04
NOMESCO Finland
NA
121.1
31.2
33
*
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
22.3
31.0
45
23
G04BD09
ATC
trospium; oral
36.4
30.7
39
12
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
9.1
30.4
67
89
L03AB13
ATC
peginterferon beta-1a; parenteral
329.5
30.3
30
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
5.2
29.4
103
258
XCK00
NOMESCO Finland
Perimetry
9.6
29.2
62
77
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
292.4
27.1
27
*
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
7.1
21.9
56
92
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
11.1
21.0
40
40
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.4
20.9
67
147
H02AB04
ATC
methylprednisolone; systemic
4.0
19.8
90
280
ZX120
NOMESCO Finland
Intravenous
4.9
19.0
66
158
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
15.7
18.0
29
20
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
39.0
17.8
22
6
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
25.6
17.6
24
10
R35
ICD-10 Finland
Polyuria
8.1
17.6
40
55
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
17.4
16.8
26
16
UKC02
NOMESCO Finland
Cystoscopy
4.8
16.8
59
142
XKC03
NOMESCO Finland
Water cystometry
14.4
16.8
28
21
G04BD08
ATC
solifenacin; oral
7.4
16.6
40
60
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
35.2
15.9
20
6
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
10.4
15.0
29
30
N06BA07
ATC
modafinil; oral
19.5
14.9
22
12
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
5.9
14.8
42
79
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
4.6
14.7
53
131
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
37.8
14.6
18
5
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
9.7
14.0
28
31
R1250
NOMESCO Finland
Evaluation of functional capability
9.1
13.5
28
33
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
27.0
13.5
18
7
H53.2
ICD-10 Finland
Diplopia
10.3
13.5
26
27
G04BD07
ATC
tolterodine; oral
9.1
13.0
27
32
XCW99
NOMESCO Finland
Other investigative procedure of eye
4.4
12.8
47
118
TKC22
NOMESCO Finland
Catheterisation instruction
13.9
12.6
21
16
R4110
NOMESCO Finland
Physiotherapy
2.6
12.1
107
512
N03AX12
ATC
gabapentin; oral
3.1
11.9
73
276
R4150
NOMESCO Finland
Neuropsychological rehabilitation
19.8
11.7
17
9
XCD10
NOMESCO Finland
Electrophysiological examination of eye
10.6
11.2
21
21
G04BD04
ATC
oxybutynin; oral, transdermal
6.7
10.9
27
43
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
4.7
10.7
36
83
A02BC02
ATC
pantoprazole; systemic
2.1
10.5
224
1591
N06AX16
ATC
venlafaxine; oral
2.7
10.3
80
349
R33
ICD-10 Finland
Retention of urine
6.6
10.1
25
40
L04AA40
ATC
cladribine; oral
56.6
9.7
11
*
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
+∞
9.4
9
*
3773B
ICD-9 Finland
Disorders of optic nerve and visual pathways, Optic neuritis[NEURITIS RETROBULBARIS]
+∞
9.4
9
*
N03AE01
ATC
clonazepam; systemic
4.2
8.9
33
84
H53.1
ICD-10 Finland
Subjective visual disturbances
3.7
8.7
37
107
N03AX16
ATC
pregabalin; oral
2.3
8.6
92
472
J01EA01
ATC
trimethoprim; systemic
2.2
8.6
100
537
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
92.2
8.4
9
*
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
34.2
8.1
10
*
R42
ICD-10 Finland
Dizziness and giddiness
2.5
8.0
69
318
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
6.2
7.8
20
34
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
5.4
7.7
22
43
N04BD01
ATC
selegiline; oral
18.9
7.6
11
6
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
12.2
7.6
13
11
SPAT1229
SPAT
Assessment of need for aid
4.3
7.6
27
67
R4120
NOMESCO Finland
Occupational therapy
3.5
7.5
34
104
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
81.8
7.4
8
*
XKD03
NOMESCO Finland
Urethral pressure profilometry
11.2
7.4
13
12
SPAT1216
SPAT
Assessment of functional ability
3.0
7.3
41
146
N06
ICPC
Sensation disturbance other
16.2
7.3
11
7
N32.82
ICD-10 Finland
Instability of the detrusor vesicae muscle
16.2
7.3
11
7
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
30.7
7.2
9
*
N02BE01
ATC
paracetamol; systemic, rectal
2.1
7.1
293
2477
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.1
7.1
86
465
CS5Z4
NOMESCO Finland
Specialised imaging for glaucoma
14.1
6.9
11
8
M03BX02
ATC
tizanidine; oral
1.9
6.8
248
1979
4AA23
NOMESCO Finland
NA
40.9
6.8
8
*
AA1AG
NOMESCO Finland
Short MRI examination of brain with median intensity magnet
7.4
6.8
15
21
R90.8
ICD-10 Finland
Other abnormal findings on diagnostic imaging of central nervous system
10.3
6.6
12
12
TKC20
NOMESCO Finland
Catheterisation of bladder
4.1
6.5
24
62
N39.4
ICD-10 Finland
Other specified urinary incontinence
3.5
6.3
28
85
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.7
6.3
41
163
L01BB04
ATC
cladribine; systemic
+∞
6.3
6
*
G37.8
ICD-10 Finland
Other specified demyelinating diseases of central nervous system
+∞
6.3
6
*
N31.0
ICD-10 Finland
Uninhibited neuropathic bladder, not elsewhere classified
27.2
6.3
8
*
N06AA09
ATC
amitriptyline; systemic
2.8
6.1
37
140
CS434
NOMESCO Finland
Visual field testing with Humphrey automated perimetry
8.8
6.1
12
14
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
129
60
31.44
181.66
1.2
1.1
—
—
—
0
0
89
22
51.93
150.86
1.0
1.1
—
—
—
0
0
90
29
39.90
142.04
1.0
1.1
212.4
228.3
mg/l
0.25
75
23
90
30
38.56
140.58
1.1
1.2
54.5
31.7
mg/l
3.97
71
24
169
247
11.21
120.75
3.1
2.7
9.6
10.4
g/l
2.18
155
231
386
1862
48.01
102.76
13.4
8.9
3.2
4.0
e9/l
20.96
371
1635
110
112
13.23
100.93
2.1
1.7
0.0
0.0
iu/ml
—
6
14
74
36
25.06
100.24
1.0
1.1
—
—
—
0
0
73
36
24.65
98.29
1.0
1.1
—
—
—
0
0
71
38
22.56
92.18
1.0
1.1
—
—
—
0
0
61
23
31.18
90.54
1.0
1.1
1.0
1.2
u/l
—
19
9
55
18
35.34
85.26
1.2
1.1
1614.6
1789.1
miu/ml
0.29
55
18
86
77
14.00
85.06
1.1
1.3
149.5
9.8
e6/l
0.50
72
60
86
77
14.00
85.06
1.1
1.4
62.8
195.8
e6/l
0.62
73
63
78
78
12.21
71.39
1.0
1.3
3.5
3.5
mmol/l
0.30
73
73
48
23
23.62
64.71
2.4
2.4
13.9
12.8
%
0.15
20
13
60
46
15.20
64.50
1.3
1.1
—
—
—
0
0
42
29
16.09
47.47
2.9
2.1
994.3
864.6
e6/l
0.40
28
11
49
5
111.57
45.94
1.2
1.0
—
—
—
0
0
266
1259
4.41
43.97
2.5
2.3
98.5
73.5
nmol/l
19.18
260
1194
184
673
4.25
43.83
3.8
2.4
0.1
0.3
e6/l
1.39
156
489
217
896
4.16
43.45
4.6
2.7
—
—
—
0
0
29
11
28.37
42.22
2.8
2.2
—
—
—
0
0
34
20
18.51
41.51
2.6
2.6
—
—
—
0
0
103
267
4.87
38.03
2.5
2.2
36.4
17.3
au/ml
—
6
18
310
1891
3.97
30.12
6.9
3.5
—
580.2
—
0
26
111
379
3.68
27.43
3.6
2.2
0.9
1.0
e6/l
0.12
68
193
100
369
3.29
21.39
3.5
2.3
6.5
3.2
e6/l
1.47
57
184
39
71
5.99
20.99
4.2
4.0
3.1
4.4
e9/l
3.94
39
71
39
71
5.99
20.99
4.2
4.3
55.0
58.0
%
0.67
39
71
230
1468
2.36
15.35
3.3
5.5
9.2
10.3
umol/l
1.70
225
1399
233
1515
2.31
14.62
5.4
2.8
0.0
0.0
estimate
0.00
55
292
233
1518
2.30
14.51
7.6
3.9
0.0
0.0
estimate
0.50
57
300
233
1532
2.27
14.01
5.4
2.8
0.0
0.0
estimate
0.80
57
287
179
1089
2.18
12.67
3.5
4.3
39.0
37.4
g/l
5.89
171
1024
61
239
2.84
11.33
2.7
2.2
59.0
1742.5
u/l
3.16
16
101
13
14
9.57
10.82
1.3
1.7
—
—
—
0
0
227
1575
2.04
10.72
2.4
3.9
5.8
6.4
mmol/l
7.18
215
1450
379
3333
4.38
9.08
10.0
10.1
16.6
19.3
mg/l
1.01
284
2511
40
143
3.00
8.72
1.3
2.3
68.9
68.4
g/l
0.24
40
135
39
141
2.96
8.34
1.3
1.4
—
—
—
0
0
357
3087
2.63
7.80
9.1
8.2
96.9
93.1
ml/min/173m2
4.01
311
2521
11
6
18.80
7.64
2.6
1.8
—
—
—
0
0
343
2928
2.30
7.47
18.8
12.1
13.2
13.4
%
4.83
343
2873
43
186
2.47
6.52
2.5
1.6
—
—
—
0
0
170
1199
1.73
6.51
6.1
2.7
—
—
—
0
0
395
3799
+∞
6.11
24.5
15.0
137.4
137.2
g/l
0.10
395
3770
361
3213
2.44
6.05
8.9
9.6
3.9
3.9
mmol/l
1.70
354
3125
281
2306
1.76
5.96
4.7
6.7
73.9
73.5
u/l
0.06
264
2182
20
69
3.00
4.67
1.1
2.0
—
—
—
0
0
12
30
4.09
4.47
1.4
1.6
—
—
—
0
0
153
1139
1.56
4.28
3.0
3.2
28.2
30.9
u/l
0.59
148
1096
275
2346
1.57
4.03
2.8
3.8
8.2
8.5
mm/h
0.18
255
2229
6
7
8.68
3.27
1.2
1.1
—
—
—
0
0
6
7
8.68
3.27
1.2
1.3
—
—
—
0
0
301
3288
0.64
3.25
3.1
3.5
1.5
1.5
mmol/l
0.70
283
3151
335
3050
1.65
3.18
4.8
4.7
1.6
2.1
mu/l
0.77
322
2929
105
764
1.51
3.11
6.9
3.0
0.0
0.0
estimate
0.80
58
299
6
8
7.59
3.06
1.2
1.4
—
—
—
0
0
5
180
0.27
3.04
1.2
1.4
—
—
—
0
0
5
180
0.27
3.04
1.2
1.4
—
—
—
0
0
5
180
0.27
3.04
1.2
1.4
—
—
—
0
0
5
180
0.27
3.04
1.2
1.4
—
—
—
0
0
12
303
0.38
2.99
1.7
1.5
—
—
—
0
0
307
3319
0.66
2.78
3.5
3.7
3.0
3.0
mmol/l
0.51
291
3170
6
187
0.31
2.73
1.3
1.5
—
—
—
0
0
291
3174
0.68
2.69
2.9
3.2
1.2
1.3
mmol/l
0.49
273
3037
33
185
1.86
2.66
1.2
1.4
185.6
263.6
miu/ml
—
8
100
5
7
7.22
2.55
1.2
1.6
—
—
—
0
0
7
16
4.43
2.48
1.0
1.0
—
—
—
0
0
5
8
6.31
2.38
1.2
1.1
—
—
—
0
0
7
18
3.94
2.26
1.0
1.2
—
—
—
0
0
9
30
3.05
2.16
1.1
1.3
—
—
—
0
0
308
3296
0.70
2.14
3.2
3.5
4.9
4.9
mmol/l
0.46
293
3165
117
933
1.36
2.02
1.7
1.7
102.3
98.5
pmol/l
0.38
64
517
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
17
3.57
1.84
1.0
1.2
—
—
—
0
0
17
87
2.00
1.82
2.1
2.2
—
—
—
0
0
16
82
1.99
1.72
2.1
1.9
—
—
—
0
0
269
2909
0.76
1.68
3.4
3.8
—
—
—
0
0
288
2655
1.31
1.61
4.1
4.1
14.2
14.3
pmol/l
0.17
277
2528
262
2832
0.78
1.54
3.4
4.1
35.6
37.8
mmol/mol
6.09
251
2728
11
215
0.50
1.50
3.6
7.4
1.0
1.0
mmol/l
—
6
162
142
1219
1.26
1.36
5.1
5.8
1.2
1.2
mmol/l
2.09
119
1037
18
105
1.75
1.35
1.3
1.6
—
—
—
0
0
0
37
0.00
1.35
0.0
1.4
—
—
—
0
0
11
205
0.52
1.32
1.9
1.8
—
—
—
0
0
12
215
0.54
1.27
3.4
7.4
12.3
13.8
kpa
1.02
12
205
12
215
0.54
1.27
3.4
7.4
5.0
5.2
kpa
0.35
12
204
101
844
1.26
1.21
1.5
1.5
—
—
—
0
0
47
355
1.37
1.16
1.9
2.0
5.9
7.0
umol/l
0.24
39
307
5
20
2.52
1.15
1.0
1.8
2.0
3.5
mg/l
—
5
20
11
193
0.56
1.10
1.3
1.9
2.0
2.6
mg/l
—
6
137
46
350
1.36
1.09
1.5
1.8
—
—
—
0
0
16
97
1.68
1.08
1.1
1.1
3.5
1.4
u/ml
—
5
34
39
516
0.73
1.08
1.6
1.7
—
—
—
0
0
5
22
2.29
1.03
1.0
1.2
—
—
—
0
0
19
123
1.57
1.01
1.2
2.7
—
—
—
0
0
56
449
1.29
0.94
2.1
3.1
565.0
394.7
ng/l
0.14
25
247
36
271
1.36
0.93
3.5
3.2
28.6
31.0
%
0.78
30
207
123
1079
1.20
0.93
3.9
5.0
1.2
1.2
mmol/l
1.38
113
994
12
192
0.61
0.88
2.8
4.0
1.9
5.6
ug/l
1.64
12
143
33
432
0.74
0.87
1.4
1.9
—
—
—
0
0
8
141
0.56
0.84
1.8
1.5
—
—
—
0
0
14
213
0.64
0.84
1.6
2.3
14.2
13.6
nmol/l
0.08
14
201
8
46
1.75
0.83
1.0
1.1
—
—
—
0
0
8
46
1.75
0.83
1.0
1.1
—
—
—
0
0
0
24
0.00
0.79
0.0
1.0
—
—
—
0
0
6
33
1.83
0.79
1.0
1.2
—
—
—
0
0
6
33
1.83
0.79
1.0
1.2
—
—
—
0
0
6
33
1.83
0.79
1.0
1.2
—
—
—
0
0
0
26
0.00
0.78
0.0
1.5
—
—
—
0
0
0
26
0.00
0.78
0.0
1.4
—
—
—
0
0
127
1409
0.85
0.74
3.3
3.7
—
—
—
0
0
30
229
1.34
0.73
1.9
2.7
—
—
—
0
0
5
27
1.86
0.68
1.4
1.6
0.6
1.0
g/l
—
5
27
85
742
1.19
0.68
1.5
1.7
0.4
0.7
mg/l
5.00
58
548
7
43
1.64
0.67
1.0
1.1
—
—
—
0
0
0
20
0.00
0.60
0.0
1.5
—
—
—
0
0
0
21
0.00
0.60
0.0
1.7
—
—
—
0
0
0
21
0.00
0.60
0.0
1.7
—
—
—
0
0
0
21
0.00
0.60
0.0
1.7
—
—
—
0
0
0
21
0.00
0.60
0.0
10.3
—
39.4
—
0
10
27
340
0.78
0.58
1.3
1.9
—
—
—
0
0
100
898
1.15
0.57
2.4
2.6
90.1
17.5
ng/l
0.46
57
393
8
122
0.65
0.55
1.6
1.8
—
—
—
0
0
9
60
1.51
0.54
1.3
1.4
—
—
—
0
0
6
38
1.59
0.54
1.5
1.4
—
—
—
0
0
6
38
1.59
0.54
1.5
1.4
—
—
—
0
0
6
38
1.59
0.54
1.5
1.4
—
—
—
0
0
6
39
1.55
0.53
1.5
1.4
—
—
—
0
0
6
40
1.51
0.52
1.5
1.4
—
—
—
0
0
6
40
1.51
0.52
1.5
1.4
—
—
—
0
0
6
40
1.51
0.52
1.0
2.3
—
—
—
0
0
17
127
1.35
0.50
1.3
1.7
0.2
0.2
g/l
0.24
17
122
17
127
1.35
0.50
1.1
1.1
—
—
—
0
0
17
223
0.75
0.50
1.6
2.1
15.2
38.6
u/ml
1.41
17
212
18
234
0.76
0.50
1.7
1.4
—
—
—
0
0
21
163
1.30
0.49
1.2
1.7
—
—
—
0
0
7
45
1.57
0.49
1.3
1.3
—
—
—
0
0
27
218
1.26
0.48
1.9
4.2
202.2
236.1
u/l
1.57
27
211
5
81
0.61
0.46
2.4
1.9
13.2
13.2
%
—
5
81
5
83
0.60
0.46
1.2
1.2
4.6
2.9
ug/l
—
5
75
42
359
1.19
0.45
1.4
1.3
35.0
27.4
iu/l
0.57
36
311
99
905
1.13
0.44
1.9
2.4
48.2
56.0
u/l
2.45
92
849
298
3063
0.89
0.43
3.2
3.4
5.5
5.7
mmol/l
1.85
276
2896
17
131
1.31
0.43
1.2
1.6
1.1
1.2
g/l
0.52
17
124
6
94
0.63
0.42
2.5
2.0
89.0
96.8
%
—
6
88
5
32
1.57
0.42
1.0
1.2
—
—
—
0
0
5
32
1.57
0.42
1.0
1.2
—
—
—
0
0
23
282
0.80
0.42
3.5
5.2
—
—
—
0
0
25
204
1.24
0.42
12.5
12.5
1.0
1.1
inr
—
8
34
0
15
0.00
0.41
0.0
2.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.8
—
—
—
0
0
0
16
0.00
0.41
0.0
1.8
—
—
—
0
0
0
16
0.00
0.41
0.0
1.8
—
—
—
0
0
0
16
0.00
0.41
0.0
2.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.8
—
—
—
0
0
0
17
0.00
0.40
0.0
3.4
—
596.9
—
0
17
0
19
0.00
0.39
0.0
2.0
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
24.0
—
0
19
18
225
0.79
0.39
1.4
1.5
—
—
—
0
0
74
671
1.13
0.38
1.3
1.3
14.0
24.6
iu/ml
0.97
15
221
9
68
1.33
0.38
1.9
3.4
—
845.7
—
0
7
97
896
1.11
0.36
2.1
3.0
2.3
2.4
mmol/l
0.16
88
826
23
191
1.22
0.34
1.8
1.5
—
—
—
0
0
7
52
1.35
0.31
1.9
3.4
—
5348.0
—
0
5
28
240
1.18
0.31
1.2
1.6
—
—
—
0
0
7
99
0.70
0.31
4.7
8.8
24.9
24.0
mmol/l
—
7
94
16
130
1.24
0.29
1.3
1.7
—
—
—
0
0
10
76
1.32
0.28
1.1
1.3
—
1.2
—
0
5
71
766
0.91
0.27
1.4
1.6
1.6
1.5
mmol/l
0.53
64
683
8
67
1.20
0.26
2.1
1.5
—
—
—
0
0
35
311
1.14
0.26
2.0
2.8
20.2
23.1
%
0.37
13
88
16
134
1.20
0.23
4.4
3.1
5.1
5.1
kpa
0.00
16
126
0
11
0.00
0.21
0.0
1.6
—
196.4
—
0
11
0
11
0.00
0.21
0.0
2.5
—
34.0
—
0
11
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
7.7
—
0
10
8
103
0.77
0.21
2.8
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
3.0
—
131.3
—
0
12
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
62
661
0.93
0.19
1.2
1.3
2.6
11.1
u/ml
2.02
23
302
27
243
1.12
0.17
1.2
1.7
—
—
—
0
0
26
234
1.12
0.17
1.8
1.9
0.6
0.6
ug/l
0.24
19
103
5
68
0.73
0.17
1.4
1.2
—
—
—
0
0
90
940
0.94
0.16
1.7
1.6
—
—
—
0
0
10
83
1.21
0.15
1.5
1.0
1.1
1.3
u/ml
—
5
42
76
724
1.06
0.15
1.5
2.1
—
—
—
0
0
12
104
1.16
0.12
1.1
1.3
—
3.3
—
0
10
6
56
1.07
0.08
1.0
1.2
—
—
—
0
0
24
225
1.07
0.07
1.2
1.0
—
—
—
0
0
8
76
1.05
0.07
1.0
1.2
—
—
—
0
0
8
77
1.04
0.07
1.8
1.7
—
—
—
0
0
8
78
1.03
0.07
1.9
1.9
208.0
232.7
pmol/l
—
8
73
334
3322
1.04
0.06
15.8
10.8
41.0
40.8
%
0.37
268
2866
67
653
1.03
0.05
1.5
2.0
—
—
—
0
0
87
883
0.98
0.03
1.3
1.3
0.5
1.9
u/ml
1.53
17
260
67
660
1.02
0.02
2.0
1.9
—
—
—
0
0
63
639
0.98
0.02
2.0
2.1
2.6
2.8
mg/l
0.34
55
557
10
107
0.93
0.02
1.2
1.2
—
—
—
0
0
164
1649
0.99
0.01
2.5
2.8
96.8
88.7
ug/l
0.35
155
1580
10
106
0.94
0.01
1.2
1.2
—
—
—
0
0
41
411
1.00
0.00
2.0
3.0
483.8
636.5
ng/l
0.23
29
339
12
123
0.97
0.00
1.1
1.3
—
—
—
0
0
35
355
0.98
0.00
1.3
1.2
215.5
158.2
iu/ml
0.35
14
156
21
214
0.98
0.00
1.8
2.1
80.3
79.0
ml/min/173m2
0.05
12
84
40
396
1.01
0.00
2.0
2.8
0.9
0.8
mmol/l
1.03
40
376
0
6
0.00
0.00
0.0
1.0
—
1.2
—
0
6
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
8
88
0.91
0.00
1.6
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
3.6
—
—
—
0
0
0
9
0.00
0.00
0.0
2.9
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
0.00
0.0
4.4
—
—
—
0
0
0
8
0.00
0.00
0.0
4.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
12
120
1.00
0.00
4.5
5.7
25.5
24.6
mmol/l
0.64
12
120
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
2.9
—
—
—
0
0
9
90
1.00
0.00
1.9
2.6
24.9
23.9
mmol/l
—
9
82
0
6
0.00
0.00
0.0
1.2
—
15.2
—
0
6
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
13
130
1.00
0.00
1.7
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
104.3
—
0
8
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: MSMED_TERIFLUNOMIDE – Use of teriflunomide
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).